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Cancer Research UK Formulation Unit




To develop novel anti-cancer drugs selected by Cancer Research 
UK New Agents Committee for Phase I and II Clinical Trial
Pharmaceutical Translation Research
 Established in 1983
Bench to Bedside  ?Powder to Product  ?Molecule to Medicine
Pharmaceutical Development
Synthesis Analysis Formulation Stability Testing

























Early Example - 1984
 1, 2, 4-triglycidyl urazol -
Limited solubility & stability
 Reconstitution Fluid






















































therapy, >18 yrs, 
















 Majority of formulations injections
 Drug solubility
Range of formulation techniques applied
 Drug stability










Oral Bioavailability 98% 
Solubility sparingly
Oral Bioavailability 31% 
Solubility (1:2 DMSO:PBS) 0.3mg/ml
Oral Bioavailability 50% 
Intestinal Solubility Variation
 Impact of simulated gastrointestinal fluid composition




























































 Low solubility 
Slower dissolution












































































































 Majority of formulations oral





 Smaller patient numbers

































 This is not new!
Future Pharmaceutical  Challenge
Does one formulation and manufacturing technology fit all?
Solutions  ?scaleable, quick, agile, low cost, GMP compliant, patient friendly
Are there other aspects that can change?
Basic and applied research required
3D Printing
Just in time manufacture
Small scale development
Individual patient trials
3D Printing & Injection Moulding
 Hot topic  ?a la mode




 Multiple areas of research






























































































































































Predict, Integrate, Design, Test
Discovery Development Treatment
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